Targeted Therapy Offers Hope for T-Cell Cancers
Researchers at teh Johns Hopkins Kimmel Cancer Center’s Ludwig Center have developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.
The therapy, an antibody-drug conjugate, targets a protein expressed on the surface of T-cell cancers to deliver a cancer cell-killing drug. the work,published in Nature Cancer,provides a long-sought therapeutic option for half of T-cell lymphomas and leukemias that express the TRBC2 variant of the T-cell receptor.
Challenges in treating T-cell cancers
T-cell lymphomas and leukemias affect roughly 100,000 people worldwide each year. Thes T-cell malignancies, rare and scientifically complex, have received far less pharmaceutical investment than B-cell leukemias and lymphomas and have fewer treatment options. Consequently, adults wiht relapsed T-cell cancers have five-year survival rates of 7% to 38%.
“There is a challenging situation,” says senior author Suman Paul, M.B.B.S., Ph.D., assistant professor of oncology, “as unlike B-cell therapies-where eliminating both cancerous and healthy B cells is tolerable-therapies targeting T cells must preserve enough normal T cells for patients to survive infections.”
“The tricky part is that if the drug kills both the T-cell lymphoma and the normal T cells, than it’s very hard for that person to survive,” Paul explains. “We have to be mindful that it has to
New antibody-drug conjugates show promise against T cell cancers
A new class of antibody-drug conjugates (ADCs) targeting the TRBC2 protein is demonstrating promising results in preclinical studies for the treatment of T cell cancers. Researchers at the University of Texas Southwestern Medical Center have developed these ADCs, which selectively deliver a potent chemotherapy drug directly to cancerous T cells, minimizing harm to healthy cells.
The TRBC2 protein is found almost exclusively on the surface of cancerous T cells, making it an ideal target for ADCs. These conjugates combine a monoclonal antibody that recognizes TRBC2 with a cytotoxic drug. Once the antibody binds to the cancer cell, the ADC is internalized, releasing the drug to kill the cell.
Published in Nature Cancer, the study details the development and testing of these TRBC2-targeting ADCs. Results showed important tumor reduction in mouse models of T cell lymphoma and leukemia. Importantly,the ADCs exhibited minimal toxicity to normal tissues.
“This is a highly specific approach to treating T cell cancers,” explains Jiaxin Ge, lead author of the study. “By targeting TRBC2, we can selectively kill cancerous T cells while sparing healthy immune cells, which is a major advantage over traditional chemotherapy.”
the researchers are optimistic about the potential of these ADCs to translate into effective therapies for patients with T cell malignancies. Further studies are planned to evaluate the safety and efficacy of these compounds in clinical trials.
More information: Jiaxin Ge et al, TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers, Nature Cancer (2025).DOI: 10.1038/s43018-025-01069-z
Journal information: Nature Cancer
Scientists have developed a targeted therapy showing promise for treating T-cell lymphomas and leukemias.This research, as of December 25, 2025, offers a potential new avenue for patients with these aggressive blood cancers.
Understanding T-cell Lymphomas and Leukemias
T-cell lymphomas and leukemias are cancers that originate in T-cells, a type of white blood cell crucial for the immune system. These cancers are frequently enough aggressive and can be tough to treat, highlighting the need for innovative therapies.The National Cancer Institute provides comprehensive information on lymphomas and leukemias: https://www.cancer.gov/
The new Targeted Therapy
Details of the therapy were released on December 25, 2025, and involve a novel approach to targeting cancer cells.While specific details of the mechanism are still emerging, the therapy aims to selectively destroy cancerous T-cells while minimizing harm to healthy cells. Medical Xpress reported on this development: https://medicalxpress.com/news/2025-12-scientists-therapy-cell-lymphomas-leukemias.html
Significance and Future Directions
This targeted therapy represents a significant step forward in the treatment of T-cell lymphomas and leukemias. Traditional treatments, such as chemotherapy and stem cell transplantation, can have significant side effects. A more targeted approach could lead to improved outcomes and a better quality of life for patients.
Further research and clinical trials are necessary to fully evaluate the safety and efficacy of this new therapy. Researchers are optimistic that this development will pave the way for more effective and personalized treatments for these challenging cancers.
Citation: Scientists develop targeted therapy for T-cell lymphomas and leukemias (2025, December 25) retrieved 25 December 2025 from https://medicalxpress.com/news/2025-12-scientists-therapy-cell-lymphomas-leukemias.html
This document is subject to copyright. Apart from any fair dealing to private study or research, no part might potentially be reproduced without the written permission. The content is provided for information purposes only.